Premium
Borderline resectable pancreatic cancer: rationale for multidisciplinary treatment
Author(s) -
Takahashi Shinichiro,
Kinoshita Taira,
Konishi Masaru,
Gotohda Naoto,
Kato Yuichiro,
Kinoshita Takahiro,
Kobayashi Tatsushi,
Mitsunaga Syuichi,
Nakachi Kohei,
Ikeda Masafumi
Publication year - 2011
Publication title -
journal of hepato‐biliary‐pancreatic sciences
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.63
H-Index - 60
eISSN - 1868-6982
pISSN - 1868-6974
DOI - 10.1007/s00534-011-0371-z
Subject(s) - medicine , pancreatic cancer , cancer
Background Borderline resectable pancreatic cancer (BRPC) appears to be most frequently related to a positive surgical margin and has a poor prognosis after resection. However, few reports are available on differences in tumor characteristics and prognoses among resectable pancreatic cancer (PC), BRPC, and unresectable PC. Methods Records of 133 patients resected for pancreatic ductal adenocarcinoma and 185 patients treated as locally advanced PC (LAPC) were reviewed. Results Twenty‐four patients who initially underwent resection (BRPC‐s) and 10 patients who were initially treated as LAPC (BRPC‐n) met the criteria for BRPC. Prognosis of BRPC was significantly better than that of unresectable PC, but was significantly worse than that of resectable PC. BRPC‐s showed more frequent nerve plexus invasion ( p < 0.01), portal vein invasion ( p < 0.01), and loco‐regional recurrence ( p = 0.03) than resectable PC. The positive surgical margin rate was not significantly higher in BRPC‐s (29%) than in resectable PC (19%) ( p = 0.41). Conclusions BRPC had a poorer prognosis with more local failure than resectable PC although prognosis of BRPC was significantly better than that of unresectable PC. Considering the tumor and treatment characteristics, multidisciplinary treatment including resection is required for BRPC.